The 201 Clinical Trial For Patients With Untreated Parkinson’s Disease
The 201 Clinical Trial is a trial that will explore whether a novel drug, Risvodetinib (IkT-148009), can slow or halt progression of Parkinson’s disease. The trial will also evaluate whether Risvodetinib (IkT-148009) can partially or completely restore lost function.
I encourage anyone who is newly diagnosed and not taking medication to participate. I would do it in a heartbeat if I weren't already on medication and therefore disqualified.
"Inhibikase Therapeutics’ lead product candidate, Risvodetinib (IkT-148009), is a potent, selective small-molecule medication designed and engineered as chronically administered, once-daily oral medication targeting the underlying biological mechanism resulting in Parkinson’s disease, with the goal of halting disease progression and reversing functional loss. Risvodetinib (IkT-148009) is designed to block the activation of Abl kinase, a clinically validated drug target, to halt and reverse the loss of dopamine-secreting neurons in the brain and GI tract by restoring neuroprotective mechanisms."
I hope to participate in this trial! I've got an appointment next week for a screening visit. Wish me luck!
You go salted! Being part of clinical trials has transformed my approach to my disease. It is rewarding and hopeful. I hope you get accepted but keep after it if you don't. My first trial I was chucked out on my first appointment after screening. It was devastating. Take each day as it comes and keep applying. I've now been involved with 5 trials (if you include PPMI). I'm slated to start my sixth in January.
Ambroxol clinical trials. 
Trials coming from Zhittya 
Stemregen in clinical trial
Hope bioscience is enrolling in 2 clinical trials 
